Cell-mediated immune function was assessed by both in vitro and in vivo techniques in 20 healthy women on continuous oral contraceptive medication for periods varying from 6 mo to 6 yr. Contrary to previous reports no disturbance of cell-mediated immunity was detected.
examined for the percentage of thymus-derived (T) lymphocytes and bone marrowderived (B) lymphocytes in the sample7. Lymphocytes were stimulated in tissue culture for 3 days by the mitogens PHA, concanavalin A (Con-A), and pokeweed (PWM)7, and for 7 days in Candida albicans and irradiated pooled allogeneic lymphocytes (mixed lymphocyte reaction -MLR,)8 DNA synthesis, as detected by the incorporation of tritiated thymidine, was used as a marker of lymphocyte stimulation. Microcultures utilizing a multiple automated sample harvester were used throughout. Responses are reported as stimulation indices (cpm from stimulated cells/cpm from cultured but unstimulated cells). Dose-dependent responses were sought with the mitogens. Thus, to 0.1 ml of culture media containing cells was added: 0.1 ml of a 1/500 or 1/ 10,000 dilution of PHA-P; 0.1 ml of concanavalin A at a concentration of 200 or 20 ,g/ml, and 0.1 ml of pokeweed at a concentration of 10 or 0.5 gg/ml. All of the above cultures were performed with media containing 20% pooled human plasma.
Were a humoral suppressant of cell-mediated immune responses present in the serum of women using contraceptive medication, the thorough washing the above cells received may mask, in vitro, the in vivo effect of such an agent. Hence, the sera of these subjects were examined for immunosuppressive properties. As we have previously shown that serum from a large number of healthy control subjects when added to cultures of lymphocytes from one subject may produce a two-log scatter of the standard cells response to mitogens and antigens9, we do not believe that immunosuppressive properties of a given serum can be sought by stimulating normal cells in one serum and comparing the response to that obtained in another. The test system used was to stimulate normal cells with PHA and allogeneic pooled irradiated cells in media already containing optimal amounts of pooled human plasma with or without an added 10% of the serum to be tested. Thus, the response of cells from healthy subjects in a final concentration of 30% plasma (20% pooled human plasma x 10% pooled human plasma or 20% pooled human plasma x 10% test sera) were compared using sera from 20 subjects.
RESULTS
The results are presented in Table 1 . Comparison of the mean value and the standard errors of the control group and patient group did not reveal a statistically significant difference for any of the in vitro tests although the mean values for the PHA and Con A stimulation were lower in the group taking medication when the smaller dose of mitogen was used in the cell cultures, this difference is not significant when the data are analyzed by Student's T test. A comparison of skin reactivity between the control group and contraceptive users did not suggest a diminished capacity to produce delayed hypersensitivity reactions in the latter group. A comparison of the results in individual subjects with the mean values and standard deviation of the control group did not identify any individual receiving contraceptive medication as immunosuppressed.
The sera from the contraceptive users were not immunosuppressive. The results (Mean Stimulation Index ± S E) follow: Stimulation of normal cells with high-dose PHA in pooled human plasma (30%) 56 ± 3.8; The same cells in pooled human plasma (20%) + test plasma (10%), 61 4 5.4 . With the lower dose of PHA, the indices were 31 ± 4.7 and 33 ± 5.9, respectively. For the mixed lymphocyte reaction the results were 26 3.5 in pooled plasma alone and 21 i 4.7 in pooled plasma and plasma from the contraceptive users. DISCUSS ION The assessment of cell-mediated immune (CMI) responses in humans remains difficult and it is being increasingly recognized that no one test is adequate. The approach taken in this study has been to investigate a number of correlates of CMI and to utilize dose-dependent stimulation in assaying mitogen stimulation 1. This allows detection of an abnormal responsiveness that may be missed with maximal stimulation. The problem of looking for a circulating immunosuppressive factor is also difficult. As has been shown in studies using sera from mice, human sera or plasma from one subject varies greatly in its ability to support in tissue cultures cells from another subject9. Thus, if lymphocytes from one control subject are stimulated by PHA in the presence of 50 different samples of sera or plasma from healthy subjects, a wide variation in the response of the cells is noted. It would be easy to assume that those sera associated with the lowest responses contained an immunosuppressive factor. However, that would imply active suppression when it really may be lack of some nutritive factor. In any case, as such a result can be obtained when normal sera are screened it makes it difficult to screen sera from diseased subjects for immunosuppressive factors. Our approach was to supply normal cells with pooled human plasma in optimal amounts and then add the plasma to be tested. A resulting decrease in response to stimulation would be more likely to be biologically significant and to be an active rather than a passive phenomenon. We were interested in the possible immunosuppressive properties of sera from women on oral contraceptives as a number of reports suggest that in pregnancy there is a circulating plasma factor than can suppess CMI. No such factor was found in the plasma of our subjects. Thus, despite the problems inherent in tests whose normal values include wide standard deviations, it seems clear that the commonly used oral contraceptives which feature combinations of estrogen and progestegin do not effect CMI. It is thus unlikely that the changes in immunological function seen in pregnancy are related to the development of a hormonal balance similar to that induced by oral contraceptives. Previous reports suggesting that oral contraceptives affect cell-mediated immunity have been limited in the number of patients studied and the breadth of their assessment of CMI, and insufficient information was provided to establish the similarity of the populations variously studied. Impaired CMI may predispose to cancer formation but there have been no suggestions of an increased incidence of cervical cancer among oral contraceptive users", and a lower incidence of breast cancer12 has been reported. These facts, which suggest indirectly that immunological surveillance for Cancer is not diminished by oral contraceptive preparations, are supported by the current direct evaluation of the CMI system in contraceptive users.
